Fax delays hurt both revenue and patient care. AI automation can remove bottlenecks for faster, better outcomes.
Fax delays are slowing care and revenue — how AI speeds workflows Read More »
How AI and automation can help payers drive revolutionary new efficiencies in provider lifecycle management (PLM), medical management and member outreach and support.
Leveraging automation and AI to transform payer operations Read More »
La inteligencia artificial (IA) está transformando múltiples ámbitos de la sociedad, y la conservación de especies en peligro de extinción no es la excepción. En un mundo donde la pérdida de biodiversidad avanza a un ritmo alarmante —con miles d …
Inteligencia artificial, una aliada clave en la conservación de especies en peligro Read More »
La arqueología, tradicionalmente asociada a excavaciones con pinceles y palas, ha experimentado una auténtica revolución en las últimas décadas gracias a la tecnología moderna. Hoy, disciplinas como la teledetección, la inteligencia artificial o la ge …
La pregunta sobre si estamos solos en el universo sigue siendo uno de los mayores enigmas científicos de nuestro tiempo. Aunque Marte, Europa o Encélado suelen acaparar la atención como candidatos a albergar vida extraterrestre, algunos investigadores han propuesto un escenario …
Formas de vida hipotéticas en la atmósfera de Júpiter Read More »
La medicina estética está viviendo una auténtica revolución gracias a la investigación con células madre. Estos recursos biológicos, capaces de transformarse en distintos tipos de tejidos y estimular procesos de reparación, se están posi …
Células madre y medicina estética: la revolución regenerativa del antiaging Read More »
From more than 30 target action dates in the last three months of the year, BioSpace has narrowed the list to six regulatory decisions that could have far-reaching implications for biopharma and patients.
In one of the first demonstrations of the impact of last year’s Loper Supreme Court decision on challenges to agency authority, a judge ruled that the FDA does not have authority to regulate tests developed by clinical laboratories.
By publishing complete response letters as soon as they are issued to drug sponsors, the FDA is expanding transparency in a way that, while positioned as a public health measure, also grants investors greater visibility into regulatory decisions. Experts question whether this is the agency’s proper remit.
Wall Street the Main Beneficiary of FDA’s Real-Time CRL Disclosures Read More »
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and granted approvals in Barth syndrome and for a subcutaneous version of Merck’s Keytruda that could be key to the blockbuster’s future earnings.
September’s FDA Action Bolsters Keytruda, Ultra-Rare Disease but Deals Two SMA Defeats Read More »
